非何杰金氏淋巴瘤药物市场规模、份额、成长分析（按治疗类型、药物类别、给药途径、适应症和地区）—2025 年至 2032 年产业预测

2023 年全球非何杰金氏淋巴瘤药物市场规模价值 52 亿美元，预计将从 2024 年的 55.6 亿美元成长到 2032 年的 94.8 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.9%。

全球非何杰金氏淋巴瘤(NHL) 药物市场正在经历显着成长，主要原因是人口老化导致 NHL 发病率上升，以及诊断技术的进步使得早期发现成为可能。患者数量的增加导致对有效治疗的需求增加，促使製药公司和医疗保健提供者专注于开发新治疗方法。此外，研发投资也大幅增加，推动了市场的扩张。一个显着的趋势是免疫疗法的进步，特别是嵌合体抗原受体 (CAR) T 细胞疗法，它可以有效地瞄准和摧毁癌细胞。这些创新疗法改善了患者的治疗效果，促进了向个人化治疗方案的转变，进一步推动了非何杰金氏淋巴瘤药物产业的成长。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

非何杰金氏淋巴瘤药物市场规模（依治疗类型及复合年增长率）（2025-2032）

• 市场概览
• 化疗
• 免疫疗法
• 标靶治疗
• 放射治疗

非何杰金氏淋巴瘤药物市场规模（依药物类别及复合年增长率）（2025-2032）

• 市场概览
• 单株抗体
• 化疗药物
• 布鲁顿蛋白酪氨酸激酶抑制剂
• 免疫调节药物

非何杰金氏淋巴瘤药物市场规模（依给药途径及复合年增长率）（2025-2032）

• 市场概览
• 静脉
• 口服
• 皮下

非何杰金氏淋巴瘤药物市场规模（依适应症和复合年增长率）（2025-2032）

• 市场概览
• 瀰漫大B细胞淋巴瘤
• 滤泡性淋巴瘤
• 套细胞淋巴瘤
• 套件淋巴瘤

非何杰金氏淋巴瘤药物市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Roche（Switzerland）
• Novartis（Switzerland）
• Gilead Sciences（USA）
• Bristol-Myers Squibb（USA）
• AbbVie（USA）
• Merck & Co.（USA）
• AstraZeneca（United Kingdom）
• Sanofi（France）
• Bayer AG（Germany）
• Johnson & Johnson（USA）
• Pfizer（USA）
• Eli Lilly and Company（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Genmab（Denmark）
• Seagen Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Kyowa Kirin Co., Ltd.（Japan）
• Spectrum Pharmaceuticals Inc.（USA）
• Autolus Therapeutics（UK）
• Immuneel Therapeutics Private Limited（India）

结论和建议

Global Non-Hodgkin Lymphoma Therapeutics Market size was valued at USD 5.2 billion in 2023 and is poised to grow from USD 5.56 billion in 2024 to USD 9.48 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The global Non-Hodgkin Lymphoma (NHL) therapeutics market is experiencing significant growth, driven by the rising incidence of NHL, primarily due to an aging population and advancements in diagnostic technologies that enable earlier detection. This increasing patient base is resulted in a higher demand for effective treatments, prompting pharmaceutical companies and healthcare providers to focus on developing new therapeutic options. Additionally, there is a surge in research and development investments, stimulating market expansion. A notable trend is the advancement of immunotherapy, particularly Chimeric Antigen Receptor (CAR) T-cell therapies, which effectively target and destroy cancer cells. These innovative treatments improve patient outcomes, fostering a shift toward personalized regimens and further fueling growth within the NHL therapeutics sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Hodgkin Lymphoma Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Hodgkin Lymphoma Therapeutics Market Segments Analysis

Global Non-Hodgkin Lymphoma Therapeutics Market is segmented by Therapeutic Type, Drug class, Administration Route, Indication and region. Based on Therapeutic Type, the market is segmented into Chemotherapy, Immunotherapy, Targeted Therapy and Radiation Therapy. Based on Drug class, the market is segmented into Monoclonal Antibodies, Chemotherapeutic Agents, Bruton's Tyrosine Kinase Inhibitors and Immunomodulators. Based on Administration Route, the market is segmented into Intravenous, Oral and Subcutaneous. Based on Indication, the market is segmented into Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma and Burkitt Lymphoma. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Hodgkin Lymphoma Therapeutics Market

The global non-Hodgkin lymphoma therapeutics market is primarily driven by the rising incidence of non-Hodgkin lymphoma, largely attributed to an aging population and various lifestyle factors. As the number of diagnoses continues to climb, there is an escalating need for advanced treatment solutions, including immunotherapies, chemotherapy, and targeted therapies. This heightened demand for innovative treatment options not only reflects the urgency in addressing patients' needs but also propels significant growth in the market, further encouraging research and development efforts aimed at improving patient outcomes and expanding therapeutic possibilities in combating this form of cancer.

Restraints in the Global Non-Hodgkin Lymphoma Therapeutics Market

The growth of the Global Non-Hodgkin Lymphoma Therapeutics market faces substantial obstacles, particularly in developing regions where there is a limited understanding of non-Hodgkin lymphoma. The challenges associated with early diagnosis significantly impede market progression, as insufficient healthcare infrastructure and lack of diagnostic resources create delays in identifying and treating the condition. This lack of timely intervention adversely impacts the demand for therapeutic options, ultimately constraining market expansion in these underserved areas. Addressing these awareness and infrastructure gaps is crucial for enabling better access to treatments and enhancing market potential in the long term.

Market Trends of the Global Non-Hodgkin Lymphoma Therapeutics Market

The Global Non-Hodgkin Lymphoma (NHL) therapeutics market is experiencing a significant shift towards immunotherapy, particularly with the rise of CAR-T cell therapies. This innovative approach leverages the body's immune response to effectively target and eliminate lymphoma cells, showing remarkable efficacy in patients with relapsed or refractory cases. The increasing approval of these advanced therapies, coupled with ongoing research and clinical trials, underscores a growing acceptance and demand within the healthcare community. As a result, the market is projected to expand rapidly, driven by enhancements in treatment outcomes, patient quality of life, and the potential for personalized medicine strategies in NHL management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Therapeutic Type & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Drug class & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibodies
• Chemotherapeutic Agents
• Bruton's Tyrosine Kinase Inhibitors
• Immunomodulators

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Administration Route & CAGR (2025-2032)

• Market Overview
• Intravenous
• Oral
• Subcutaneous

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Diffuse Large B-Cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Burkitt Lymphoma

Global Non-Hodgkin Lymphoma Therapeutics Market Size & CAGR (2025-2032)

• North America (Therapeutic Type, Drug class, Administration Route, Indication)
  • US
  • Canada
• Europe (Therapeutic Type, Drug class, Administration Route, Indication)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapeutic Type, Drug class, Administration Route, Indication)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapeutic Type, Drug class, Administration Route, Indication)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapeutic Type, Drug class, Administration Route, Indication)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seagen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Autolus Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immuneel Therapeutics Private Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations